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Purpose: Neurotrophin-4 protein (NT-4) plays a role in the protection of retinal ganglion cells by activating tyrosine
kinase B (TrkB) receptors. A recent study identified mutations within the neurotrophin-4 (NTF4) gene to account for 1.7%
of primary open-angle glaucoma (POAG) in Europeans. The aim of this study was to investigate the frequency of
NTF4 mutations in Chinese POAG patients.
Methods: One hundred-seventy-four Chinese subjects with POAG and 91 normal Chinese subjects were recruited. POAG
was defined by the presence of glaucomatous optic neuropathy, open angles on gonioscopy, and absence of secondary
causes of glaucoma. The single coding exon of NTF4 was PCR amplified and subjected to bidirectional sequencing in all
subjects.
Results: The mean age of POAG patients was 66.0±13.0 years (range 25–96 years) and that of controls was 67.1±4.6
years (range 60–85 years). We identified a novel NTF4 missense mutation substituting leucine by serine at codon 113
(Leu113Ser) caused by a c.338T>C mutation in a single patient with unilateral POAG, who presented with a baseline
intraocular pressure of 25 mmHg, a vertical cup-to-disc ratio of 0.9 and an inferior hemifield defect in the affected eye.
Structural analysis indicated that the Leu113Ser mutation is likely to alter the NT-4 protein structure near the TrkB binding
site and disrupts the formation of the NT-4-TrkB complex required for the activation of TrkB.
Conclusions: Identification of a single mutation in our study suggests that NTF4 mutations are a rare cause of POAG
(0.6%, 95%CI 0.02%–3.16%) in Chinese people.
Glaucoma is the leading cause of irreversible blindness
worldwide and affects about 70 million people [1,2], with
primary  open  angle  glaucoma  (POAG)  being  the  most
prevalent form of the disease. Asymptomatic in the early
stages,  POAG  is  characterized  by  a  progressive  optic
neuropathy  and  loss  of  retinal  ganglion  cells  (RGCs)  [3]
resulting  in  corresponding  loss  of  the  visual  field.  The
intraocular pressure (IOP) is often but not invariably elevated
and is considered an important risk factor contributing to
visual loss [4,5].
POAG is a complex disorder where both genetic and
environmental factors have been shown to play a part in its
development  [6].  Several  studies  have  demonstrated  a
significant familial heritable basis where a large proportion of
patients had a positive family history [4,7]. To date, 3 genes
have been identified for POAG; myocilin (MYOC or GLC1A)
[8], optineurin (OPTN or GLC1E) [9], and WD40-repeat 36
(WDR36 or GLC1G) [10], and also associated with it are a
large  number  of  genetic  variants  including  those  in
apolipoprotein E (APOE) [11], optic atrophy 1 (OPA1) [12],
and cytochrome P4501B1 (CYP1B1) [13]. Although the exact
Correspondence to: Dr. Eranga N. Vithana, Singapore Eye Research
Institute, 11 Third Hospital Avenue, Singapore, 168751; Phone:
65-63224542; FAX: 65-63224599; email: eranga.n.v@seri.com.sg
role of MYOC and OPTN in the pathogenesis of glaucoma is
unclear, studies have shown that myocilin may have a role in
trabecular meshwork homeostasis [14], while optineurin is
implicated in the neuroprotection of RGCs by reducing their
susceptibility to hydrogen peroxide-induced cell death [15].
However, mutations in these known genes account for only a
small fraction of POAG patients.
The complex nature of the disease phenotype combined
with the vast genetic heterogeneity suggests the involvement
of multiple pathological processes and molecular pathways in
POAG  causation.  Recently,  mutations  in  a  new  gene,
neurotrophin-4  (NTF4)  located  in  chromosome  19q13.33
[16], have been implicated in 1.7% of POAG patients of
European origin [17]. It has been shown that neurotrophin 4
protein (NT-4) plays a role in the protection of the RGCs by
activating the tyrosine kinase B (TrkB) receptor present in
these cells [18,19]. Low levels of TrkB expression leads to a
progressive loss of RGCs [20], a situation that also occurs
during the course of the disease process in glaucoma, which
is  reflected  as  glaucomatous  visual  field  damage.
Furthermore,  mutations  in  NTF4  resulted  in  an  in-vitro
impairment of TrkB signaling as well as neuronal growth
[17]. The recent identification in glaucoma patients, of seven
different heterozygous NTF4 mutations reveals a crucial role
of the neurotrophin signaling system in preventing neural
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1640degeneration,  thus  supporting  the  possibility  of  another
pathway in the pathogenesis of glaucoma.
The purpose of our study was to investigate the spectrum
and frequency of NTF4 mutations in our panel of Chinese
patients with POAG. In this paper we describe a rare novel
mutation of NTF4 located in the conserved region of the
protein sequence.
METHODS
Patients: Study subjects of Chinese ethnicity were recruited
from clinics at the Singapore National Eye Centre. Written,
informed consent was obtained from all subjects and the study
had the approval of the Ethics Committee of the Singapore
Eye Research Institute and was performed according to the
tenets of the Declaration of Helsinki.
Mutation  screening:  Genomic  DNA  was  extracted  from
peripheral blood leukocytes from all the subjects. The coding
regions of NTF4 were amplified by polymerase chain reaction
(PCR) with custom-designed primers. Because of it size, the
coding exon of NTF4 was divided into two overlapping PCR
fragments  amplified  by  primers  NTF4–2F1–5′-ATT  AGA
GGT  GTG  GGG  CAC  AG-3′;  NTF4–2R1–5′-CAG  CCA
CTG ACT GCA TCG-3′ and NTF4–2F2–5′- GCC CCC TCT
GCT CTT CCT-3′ NTF4–2R2–5′-TTT GAT GAG TTC CCA
AAC  TGG-3′.  PCR  reactions  were  performed  in  a  50-μl
mixture containing 10 mM Tris-HCL (pH 8.9), 50 mM KCL,
1.5  mM  MgCl2,  200  μM  each  deoxyribose  nucleoside
triphosphate,  25  picomoles  of  each  primer  (100  μM
concentration),  0.2  μl  of  HotstarTaq  DNA  polymerase
(Qiagen, GmbH, Hilden, Germany) and 4 μl of genomic DNA
(50–100  ng).  Thermal  cycling  was  performed  (DNA
Thermocycler 9700; Applied Biosystems, Foster City, CA.)
under the following conditions: initial denaturation for 15 min
at 95 °C; 40 cycles of 95 °C for 30 s, annealing variable
temperature 58 °C to 62 °C for 30 s, and extension 72 °C for
30 s; and a final extension 72 °C for 5 min. The PCR products
were analyzed on an agarose gel to confirm the product size
and  purified  using  GFX  PCR  clean  up  columns  (GFX;
Amersham,  Piscataway,  NJ).  Sequence  variations  were
identified  by  automated  bi-directional  sequencing  using
BigDye Terminator Mix v3.1; according to manufacturer’s
protocols (Applied Biosystems). Samples were denatured at
96 °C for 1 min, then cycled 25 time at 96 °C for 10 s, 50 °C
for 5 s, 60 °C for 4 min. Primers for sequence reactions were
the  same  as  those  for  the  PCR  reaction.  Removal  of
unincorporated nucleotides and purification of PCR BigDye
products were performed by ethanol precipitation at 4 °C. The
samples  were  resuspended  in  hi-di  formamide  before
sequencing.  An  automated  DNA  sequencer  (ABI  PRISM
3100; Applied Biosystems) was used. Sequence alterations
were  recorded  based  on  NTF4  cDNA  sequence  with  +1
corresponding to the A of the ATG translation initiation codon
in reference sequence NM_006179 (version NM_006179.4).
The known POAG genes MYOC, OPTN, and WDR36 were
also screened, in a single POAG patient harboring a NTF4
sequence  variation,  by  PCR  and  direct  sequencing  using
previously described conditions [21,22].
Molecular modeling: The crystal structure of the NTF4-TrkB
complex (PDB code: 1HCF) [23] was used as a template to
model the Leu113Ser mutation. The Leu113 residue of the
wild  type  protein  was  substituted  with  Ser113  using  the
PyMOL program (The PyMOL Molecular Graphics System
[2002], DeLano Scientific, Palo Alto, CA) and subjected to
energy  minimization,  using  the  Sander  module  of  Amber
simulation package [24] with force field ff94, comprising 50
steps  of  steepest  descent  with  a  cut  off  for  non-bonded
interactions of 8 Å.
RESULTS
Mutation  analysis:  One  hundred-seventy-four  Chinese
patients with POAG and 91 Chinese control subjects were
recruited in the study. The mean age of the patients was
66.0±13.0 years (range 25–96 years) and that of the controls
was 67.1±4.6 years (range 60–85 years).
Screening of NTF4 in the patients did not reveal any of
the  previously  identified  pathogenic  mutations  associated
with POAG, namely, C7Y, E84K, A88V, R90H, R206W,
R206Q, and R209G [17]. We identified a novel missense
mutation  substituting  leucine  by  serine  at  codon  113
(Leu113Ser) caused by a c.338T>C mutation in exon 2 in a
single patient with unilateral POAG (Figure 1A). To exclude
the involvement of the known POAG genes MYOC, OPTN,
and WDR36, we also re-sequenced all exons and adjacent
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All  subjects  underwent  a  standardized  ophthalmic
examination  that  included  best  corrected  Snellen  visual
acuity, slit-lamp examination (Model BQ 900; Haag-Streit,
Bern, Switzerland), stereoscopic disc examination with a 78-
diopter lens (Volk Optical Inc., Mentor, OH), gonioscopy, and
IOP  measurement  by  Goldmann  applanation  tonometer
(Haag-Streit, Koniz, Switzerland). POAG was defined by the
following  criteria:  the  presence  of  glaucomatous  optic
neuropathy (defined as loss of neuroretinal rim with a vertical
cup: disc ratio of >0.7 or an inter-eye asymmetry of >0.2, and/
or notching attributable to glaucoma) with compatible visual
field  loss,  open  angles  on  gonioscopy,  and  absence  of
secondary causes of glaucomatous optic neuropathy such as
a period of steroid administration, or uveitis. A glaucomatous
visual field defect was defined if the following were found:
(1) glaucoma hemifield test (GHT) outside normal limits, (2)
a cluster of 3 or more, non-edge, contiguous points on the
pattern deviation plot, not crossing the horizontal meridian
with  a  probability  of  <5%  being  present  in  age-matched
normals (one of which is <1%) and (3) PSD <0.05; these were
repeatable  on  two  separate  occasions.  All  normal  control
subjects had IOP<21 mmHg with open angles, healthy optic
nerves,  normal  visual  fields  and  no  family  history  of
glaucoma.splice sites of these genes in this patient. We did not find any
deleterious  protein  altering  sequence  changes  in  MYOC,
OPTN, and WDR36, indicating that these genes are unlikely
to be the cause of POAG in this patient. However, we did
identify three previously reported OPTN polymorphisms (c.
412G>A  [T34T],  IVS7+24G>A,  and  IVS15–48C>A)  and
three  WDR36  polymorphisms  (c.790A>G  [I264V],  IVS3–
113G>A, and IVS16–30A>G) in this patient. The c.338T>C
mutation in NTF4 was not found in any of our 91 normal
controls and was also located in the highly conserved mature
domain of the NT-4 protein (Figure 1B). We also did not find
this gene to be polymorphic in our patient and control sample
sets, as no other sequence change was identified besides the
c.338T>C change.
The  patient  concerned  was  a  70-year-old  lady  first
diagnosed with unilateral POAG at age 67. At presentation,
examination of the affected eye revealed a pale disc with a
vertical cup-to-disc ratio (VCDR) of 0.9, IOP of 25 mmHg
and an inferior hemifield visual field defect, while the fellow
unaffected eye had a VCDR of 0.5 with healthy neuro-retinal
rims, IOP of 15 mmHg, and normal visual field. Gonioscopy
revealed  360°  of  open  drainage  angles  in  both  eyes.  She
underwent  a  combined  phacoemulsification  and
trabeculectomy with mitomycin C application, and was on
regular follow-up. About 20 months post-surgery, the IOP
increased due to failing bleb function, and she was started on
medications to control the IOP. At final follow up, the patient
is still on medications with the IOP within acceptable limits.
Systemically, she has arterial hypertension for which she is
on treatment. Familial segregation could not be determined as
she was unmarried, and her parents were deceased and not
known if they were also affected. Her 3 siblings have not as
yet  been  diagnosed  to  have  glaucoma,  and  they  refused
genetic analysis.
DISCUSSION
In this study we identified a novel mutation (Leu113Ser) in
NTF4  in  our  analysis  of  174  POAG  patients  of  Chinese
ethnicity. Pathogenicity of this mutation is strongly supported
Figure 1. The mutation in NTF4 identified in the Chinese POAG patient. A: Sequence electropherogram of the NTF4 heterozygous mutation
c.338T>C (Leu113Ser) identified in a sporadic POAG case (left). Wild type sequence from an unaffected control individual is shown to the
right for comparison. B: Partial sequence (residues 74 to 127) of human (H. sapiens) NT-4 polypeptide compared with orthologs from other
mammalian  species  showing the  conservation  of the L113  residue as well it’s  position in relation to previously reported mutations E84K,
A88V and R90H.
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Protein modeling of the mutation: According to the known
crystal structure of the NT-4-TrkB complex Leu113 is located
near the surface of NT-4 (Figure 2 and Figure 3A) but in the
hydrophobic core comprising residues from both the chains
of  NT-4  and  a  chain  of  TrkB.  The  modeled  structure  of
Leu113Ser showed a gap (Figure 3B) compared to the wild
type structure due to the substitution with the much smaller
polar amino acid. The hydrophilic nature of the serine residue
is also likely to cause destabilization of the hydrophobic core
due to its orientation towards the solvent. As a result, it is
highly likely that Leu113Ser disrupt the integrity of both
tertiary  and  quaternary  structure  of  the  protein  complex
leading to disruption of the binding with TrkB and thus its
activation.by the fact that this change was not identified in nearly 180
control chromosomes as well by the results of our molecular
modeling.  The  structural  analysis  indicated  that  the  non-
conservative  substitution  of  this  highly  conserved,
hydrophobic residue with a strongly hydrophilic residue is
likely to drastically alter the NT-4 protein structure near the
TrkB binding site and disrupt the formation of the NT-4-TrkB
complex required for the activation of TrkB. However, it
should be noted that pathogenicity of this mutation can only
be proven conclusively through in vitro functional analysis of
the mutant protein.
We did not identify any of the NTF4 mutations previously
reported in European POAG patients in our Chinese cohort,
including the most frequent mutation R206W, suggesting that
NTF4 disease-causing mutations are ethnic specific. We also
did not find this gene to be very polymorphic in the Chinese.
Moreover, our findings of only a single mutation indicate that
NTF4 mutations are a rare cause of POAG in the Chinese.
Recently an investigation of the NTF4 gene in 443 POAG
patients of European ancestry in the south-eastern United
States found several of the risk alleles previously identified
by Pasutto et al. [17] not only in the case population, but also
among  the  control  group,  thus  casting  doubt  over  the
involvement of NT-4 in POAG causation [25]. However, the
control group used by Liu and coworkers [25] was younger
than that used by the original study; therefore the possibility
remains that some of these controls in whom ‘mutations’ were
identified may develop the disease at a later date. Analysis of
NTF4 in several more POAG cohorts of different ethnicities,
such as our study, is needed to clarify the involvement of
NTF4 in POAG.
Previous candidate gene analyses done by other groups
of known POAG genes have reported lower incidence of
MYOC  and  OPTN  mutations  in  Chinese  POAG  cohorts
compared to Caucasian patient cohorts [26-28]. The latest
POAG  gene,  NTF4,  accounted  for  1.7%  of  POAG  in
Caucasians but only 0.6% (95% Confidence Interval: 0.02 to
3.16%)  in  our  Chinese  cohort,  which  again  reflect  ethnic
variations in mutation frequencies found for POAG genes.
However,  mutations  in  the  three  known  POAG  genes
(MYOC, OPTN, and WDR36) account for no more than 10%
of POAG patients in any ethnicity. This, with the added rarity
of NTF4 mutations supports the case that POAG is more a
complex genetic disorder, with mutations within single genes
contributing only a small fraction toward its etiology.
Interestingly, the patient identified with the Leu113Ser
mutation had unilateral glaucoma. It is possible that the fellow
eye, although not affected at present, may develop glaucoma
at a later date. Unilaterality observed in our POAG patient
may also suggest that for this particular germ line mutation in
NTF4, the mutation alone is not sufficient and that additional
localized environmental factors are required to produce the
disease. In this case, we speculate that the increased IOP in
the affected eye is the most likely insult required to cause cell
death in ganglion cells with sub-optimal neuro-protection due
to the mutation in NTF4. The different IOPs in the two eyes
Figure  2.  Location  of  the  Leu113Ser
mutation in the crystal structure of the
NT-4-TrkB complex. The two chains of
the dimeric NT-4 are in cyan and blue,
respectively. The alpha carbon of the
mutated residue is shown as a magenta
sphere, with the prime symbol denoting
the residue of the second subunit. TrkB
domains are shown in orange and red
color.  The  Leu113  residue  is  located
close to the TrkB binding site.
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development  that  may  have  resulted  in  altered  outflow
pathway  mechanics  and  IOP  regulation.  The  Leu113Ser
mutation was identified in a patient with no recorded family
history  of  POAG,  and  may  therefore  represent  a  denovo
pathogenic mutation likely to segregate in a dominant fashion
in subsequent generations. We are yet unable to demonstrate
co-segregation of the mutation with disease in the family of
this  patient.  This  is  mainly  due  to  the  non-availability  of
parental DNA due to death, and also the non-compliance of
some family members for genetic analysis. We hope to follow
up on family members of this patient for future clinical and
DNA analysis.
NTF4,  a  member  of  the  neurotrophin  protein  family
which are concerned with the survival of neurons including
RGCs, is executed by the phosphorylation of TrkB receptors.
Based on their findings of the association between mutations
in  NTF4  and  POAG,  Pasutto  and  coworkers  [17]  have
demonstrated  an  impaired  TrkB  activation  as  a  possible
pathway  in  the  pathophysiology  of  glaucoma.  The
identification of mutations in NTF4 also suggests that other
members of this neutrophin protein family and its receptors
are possible good candidates to study for their involvement in
the pathogenesis of POAG.
In conclusion, we have identified a novel mutation in
NTF4  that  provides  further  evidence  that  impaired
neurotrophin signaling or compromised trophic support to the
retina may underlie ganglion cell death in POAG. This study
indicates that mutations in NTF4 only account for ≤1% of
Chinese POAG patients and is therefore a rare cause of POAG
in  the  Chinese.  However,  given  the  recent  contradictory
findings for NTF4, the screening of NTF4 in POAG patients
of other ethnicities and meta-analyses of different studies in
POAG  patients  are  required  to  establish  the  extent  of
involvement of NTF4 in glaucoma.
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